Comparison of subcutaneous and intravenous administration of the monoclonal antibody CSX-1004 on fentanyl-induced respiratory depression in squirrel monkeys
Abstract
BackgroundFentanyl and related synthetic opioids remain major contributors to overdose mortality, primarily through opioid-induced respiratory depression. CSX-1004 is a fully human monoclonal antibody designed to bind fentanyl in the peripheral circulation and prevent its entry into the brain. This study evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of intravenous (IV) and subcutaneous (SC) administration of CSX-1004 in squirrel monkeys and established a population PK (PopPK) model to support route extrapolation.MethodsProtection against fentanyl-induced respiratory depression was assessed after administration of 40 mg/kg CSX-1004 using whole-body plethysmography over 28 days. Serum antibody concentrations were quantified by enzyme-linked immunosorbent assay, and PK parameters were characterized using noncompartmental and PopPK analyses.ResultsBoth IV and SC administration produced substantial and durable attenuation of fentanyl-induced respiratory depression, resulting in a greater than 10-fold rightward shift in fentanyl potency that persisted for up to 28 days. SC CSX-1004 administration exhibited a maximum concentration of 491.7 ± 50.4 μg/mL at 48.0 ± 19.6 h (Tmax) and an absolute bioavailability of 92.0% based on AUC0−∞. Terminal half-life was comparable between routes (∼272 h). A two-compartment PopPK model with first-order absorption and elimination adequately described the concentration–time data and demonstrated robust predictive performance. Serum concentrations and respiratory protection were lower after SC than after IV administration during the first 24–48 h, reflecting the absorption phase, and converged from Day 2 onward. Simulations indicated that SC and IV administration achieved overlapping systemic exposures beyond the absorption phase and equivalent concentrations associated with sustained respiratory protection through Day 28.ConclusionThese findings demonstrate that SC administration of CSX-1004 provides PK and PD outcomes comparable to IV dosing, once absorption is complete, supporting SC delivery as a practical and clinically feasible approach for long-acting prophylaxis against fentanyl-induced respiratory depression.
Related
- Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain
- 605 Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)
- Real-world clinical outcomes under intravenous and subcutaneous esketamine protocols for treatment-resistant depression: a multicenter, retrospective study
- Part 1 of a 2-part, open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 3 consecutive days of intramuscular and subcutaneous injections
- CO002 | RETROSPECTIVE LONGITUDINAL ASSESSMENT OF JOINT HEALTH AND QUALITY OF LIFE IN ADOLESCENT AND ADULT PATIENTS AFFECTED BY MODERATE OR SEVERE HAEMOPHILIA A WITH OR WITHOUT INHIBITOR SWITCHING FROM INTRAVENOUS FVIII TREATMENT TO SUBCUTANEOUS PROPHYLAXIS WITH EMICIZUMAB
BibTeX
@article{kumar2026comparison,
title = {{Comparison of subcutaneous and intravenous administration of the monoclonal antibody CSX-1004 on fentanyl-induced respiratory depression in squirrel monkeys}},
author = {Mukesh Kumar and Emily L. Burke and Yanan Zang and Abhisheak Sharma and Paul T. Bremer and Rajeev I. Desai},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1964162},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1964162},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Comparison of subcutaneous and intravenous administration of the monoclonal antibody CSX-1004 on fentanyl-induced respiratory depression in squirrel monkeys
AU - Mukesh Kumar
AU - Emily L. Burke
AU - Yanan Zang
AU - Abhisheak Sharma
AU - Paul T. Bremer
AU - Rajeev I. Desai
PY - 2026
DA - 2026/10/30
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1964162
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1964162
AB - BackgroundFentanyl and related synthetic opioids remain major contributors to overdose mortality, primarily through opioid-induced respiratory depression. CSX-1004 is a fully human monoclonal antibody designed to bind fentanyl in the peripheral circulation and prevent its entry into the brain. This study evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of intravenous (IV) and subcutaneous (SC) administration of CSX-1004 in squirrel monkeys and established a population PK (PopPK) model to support route extrapolation.MethodsProtection against fentanyl-induced respiratory depression was assessed after administration of 40 mg/kg CSX-1004 using whole-body plethysmography over 28 days. Serum antibody concentrations were quantified by enzyme-linked immunosorbent assay, and PK parameters were characterized using noncompartmental and PopPK analyses.ResultsBoth IV and SC administration produced substantial and durable attenuation of fentanyl-induced respiratory depression, resulting in a greater than 10-fold rightward shift in fentanyl potency that persisted for up to 28 days. SC CSX-1004 administration exhibited a maximum concentration of 491.7 ± 50.4 μg/mL at 48.0 ± 19.6 h (Tmax) and an absolute bioavailability of 92.0% based on AUC0−∞. Terminal half-life was comparable between routes (∼272 h). A two-compartment PopPK model with first-order absorption and elimination adequately described the concentration–time data and demonstrated robust predictive performance. Serum concentrations and respiratory protection were lower after SC than after IV administration during the first 24–48 h, reflecting the absorption phase, and converged from Day 2 onward. Simulations indicated that SC and IV administration achieved overlapping systemic exposures beyond the absorption phase and equivalent concentrations associated with sustained respiratory protection through Day 28.ConclusionThese findings demonstrate that SC administration of CSX-1004 provides PK and PD outcomes comparable to IV dosing, once absorption is complete, supporting SC delivery as a practical and clinically feasible approach for long-acting prophylaxis against fentanyl-induced respiratory depression.
SN - 1663-9812
ER -